Alimera Sciences Company Profile (NASDAQ:ALIM)

About Alimera Sciences

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Industry, Sector and Symbol:

Sector: Medical
Industry: Drug Manufacturers - Major
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: ALIM
CUSIP:

Key Metrics:

Previous Close: $1.62
50 Day Moving Average: $1.60
200 Day Moving Average: $1.67
52-Week Range: $45,759,000.00 - $1.01
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -162.00
P/E Growth: 0.00
Market Cap: $74.13M
Outstanding Shares: 45,759,000
Beta: 2.25

Profitability:

Net Margins: -107.75%
Return on Assets: -56.31%

Debt:

Debt-to-Equity Ratio: -0.01%
Current Ratio: 0.77%
Quick Ratio: 0.74%

Additional Links:

Companies Related to Alimera Sciences:

Consensus Ratings for Alimera Sciences (NASDAQ:ALIM) (?)

Ratings Breakdown:	2 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$4.00 (146.91% upside)

Analysts' Ratings History for Alimera Sciences (NASDAQ:ALIM)

Show:

Date	Firm	Action	Rating	Price Target
9/16/2016	Cowen and Company	Upgrade	Market Perform -> Outperform	$3.00
3/4/2016	Cantor Fitzgerald	Lower Price Target	Buy	$6.00 -> $5.00
11/26/2015	Credit Suisse Group AG	Lower Price Target		$5.00 -> $4.00
11/17/2014	Summer Street	Initiated Coverage	Buy -> Buy	$12.00
9/29/2014	Northland Securities	Boost Price Target	Outperform	$7.00 -> $10.00

(Data available from 9/25/2014 forward)

Earnings History for Alimera Sciences (NASDAQ:ALIM)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/3/2016
8/3/2016	Q2	($0.19)	($0.17)	$8.42 million	$3.80 million	View	N/A
5/4/2016	Q1	($0.19)	($0.22)	$5.83 million	$5.80 million	View	N/A
11/5/2015	Q315	($0.21)	($0.21)	$6.96 million	$6.90 million	View	N/A
8/10/2015	Q215	($0.22)	($0.25)	$6.49 million	$5.80 million	View	Listen
5/7/2015	Q115	($0.24)	($0.27)	$3.90 million	$3.90 million	View	N/A
3/4/2015	Q414	$0.17	($0.28)	$5.11 million	$1.70 million	View	N/A
11/6/2014	Q314	($0.70)	($0.22)	$3.75 million	$2.40 million	View	N/A
8/7/2014	Q214	($0.23)	($0.15)	$2.70 million	$2.19 million	View	N/A
5/8/2014	Q114	($0.25)	($0.20)	$1.15 million	$2.08 million	View	N/A
2/27/2014	Q413	($0.29)	($0.24)	$0.75 million	$0.94 million	View	N/A
11/11/2013	Q313	($0.30)	($0.26)	$0.38 million	$0.76 million	View	N/A
8/12/2013	Q2 2013	($0.24)	($0.30)	$3.00 million		View	N/A
5/9/2013	Q1 2013	($0.26)	($0.27)			View	N/A
3/21/2013	Q4 2012	($0.23)	($0.17)			View	N/A
11/7/2012	Q312	($0.19)	($0.17)			View	N/A
3/8/2012		($0.24)	($0.19)			View	N/A
11/3/2011		($0.19)	($0.21)			View	N/A
8/4/2011		($0.18)	($0.17)			View	N/A
5/5/2011		($0.20)	($0.15)			View	N/A
2/10/2011		($0.22)	($0.20)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Alimera Sciences (NASDAQ:ALIM)

Current Year EPS Consensus Estimate: $-0.6 EPS
Next Year EPS Consensus Estimate: $-0.01 EPS

Dividend History for Alimera Sciences (NASDAQ:ALIM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alimera Sciences (NASDAQ:ALIM)

Insider Ownership Percentage: 18.70%
Institutional Ownership Percentage: 44.17%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/15/2016	Richard S Eiswirth Jr	Insider	Sell	51,471	$1.51	$77,721.21
4/21/2016	L.P. Bavp	Major Shareholder	Sell	478,673	$2.59	$1,239,763.07
12/16/2015	Richard S. Eiswirth, Jr.	CFO	Sell	46,669	$2.31	$107,805.39
12/8/2015	James E Flynn	Insider	Buy	272,249	$3.01	$819,469.49
12/3/2015	James E Flynn	Insider	Buy	243,252	$3.00	$729,756.00
10/30/2015	James E Flynn	Insider	Buy	16,542	$3.00	$49,626.00
10/28/2015	James E Flynn	Insider	Buy	59,342	$3.00	$178,026.00
10/26/2015	James E Flynn	Insider	Buy	60,364	$3.00	$181,092.00
10/21/2015	James E Flynn	Major Shareholder	Buy	160,684	$3.00	$482,052.00
10/20/2015	James E Flynn	Major Shareholder	Buy	100,130	$3.00	$300,390.00
10/19/2015	James E Flynn	Major Shareholder	Buy	129,226	$2.92	$377,339.92
10/15/2015	Richard S. Eiswirth, Jr.	CFO	Sell	13,625	$2.69	$36,651.25
10/9/2015	James E Flynn	Insider	Buy	321,785	$2.42	$778,719.70
9/3/2015	Calvin W Roberts	Director	Buy	6,424	$3.00	$19,272.00
8/21/2015	Kenneth Green	SVP	Sell	20,000	$3.29	$65,800.00
8/17/2015	Kenneth Green	SVP	Sell	20,000	$3.90	$78,000.00
6/26/2015	L.P. Bavp	Major Shareholder	Sell	1,024	$5.00	$5,120.00
6/19/2015	L.P. Bavp	Major Shareholder	Sell	5,568	$5.00	$27,840.00
5/1/2015	C. Daniel Myers	CEO	Sell	2,000	$4.37	$8,740.00
4/27/2015	L.P. Bavp	Major Shareholder	Sell	3,114	$5.02	$15,632.28
4/23/2015	L.P. Bavp	Major Shareholder	Sell	4,362	$5.00	$21,810.00
4/20/2015	L.P. Bavp	Major Shareholder	Sell	30,300	$5.03	$152,409.00
4/15/2015	L.P. Bavp	Major Shareholder	Sell	35,800	$5.03	$180,074.00
4/14/2015	L.P. Bavp	Major Shareholder	Sell	18,400	$5.01	$92,184.00
4/13/2015	L.P. Bavp	Major Shareholder	Sell	100	$5.00	$500.00
3/6/2015	Richard S Eiswirth Jr	CFO	Buy	10,000	$4.84	$48,400.00
3/2/2015	C. Daniel Myers	CEO	Sell	2,000	$5.21	$10,420.00
1/2/2015	C. Daniel Myers	CEO	Sell	2,000	$5.51	$11,020.00
1/2/2015	David Holland	SVP	Sell	5,000	$5.56	$27,800.00
12/1/2014	C. Daniel Myers	CEO	Sell	2,000	$5.99	$11,980.00
12/1/2014	David Holland	SVP	Sell	5,000	$5.71	$28,550.00
10/27/2014	L.P. Bavp	Major Shareholder	Sell	57,918	$6.34	$367,200.12
10/1/2014	C. Daniel Myers	CEO	Sell	2,000	$5.42	$10,840.00
10/1/2014	David Holland	SVP	Sell	5,000	$5.26	$26,300.00
10/1/2014	Patrick Lee	Major Shareholder	Sell	621,191	$5.42	$3,366,855.22
9/30/2014	Patrick Lee	Major Shareholder	Sell	354,062	$5.42	$1,919,016.04
9/29/2014	Patrick Lee	Major Shareholder	Sell	240,662	$5.47	$1,316,421.14
9/11/2014	L.P. Bavp	Major Shareholder	Sell	2,816	$6.25	$17,600.00
9/4/2014	L.P. Bavp	Major Shareholder	Sell	39,500	$6.33	$250,035.00
8/29/2014	L.P. Bavp	Major Shareholder	Sell	7,400	$6.27	$46,398.00
8/28/2014	L.P. Bavp	Major Shareholder	Sell	3,000	$6.27	$18,810.00
8/1/2014	David Holland	SVP	Sell	5,000	$5.64	$28,200.00
7/1/2014	David Holland	SVP	Sell	5,000	$6.02	$30,100.00
5/1/2014	David Holland	SVP	Sell	5,000	$5.93	$29,650.00
3/4/2014	C. Daniel Myers	CEO	Sell	22,775	$7.10	$161,702.50
3/4/2014	David Holland	SVP	Sell	10,000	$6.84	$68,400.00
3/4/2014	Susan Caballa	Insider	Sell	8,931	$7.01	$62,606.31
1/16/2014	Domain Partners Vi, L.P.	Major Shareholder	Sell	296,760	$6.39	$1,896,296.40
7/17/2013	Polaris Venture Management Co	Insider	Sell	122,937	$4.80	$590,097.60
6/20/2013	Domain Partners Vi, L.P.	Major Shareholder	Sell	10,516	$5.01	$52,685.16
6/19/2013	Domain Partners Vi, L.P.	Major Shareholder	Sell	55,278	$5.39	$297,948.42
6/18/2013	Polaris Venture Management Co	Insider	Sell	37,063	$5.44	$201,622.72
6/17/2013	Domain Partners Vi, L.P.	Major Shareholder	Sell	126,709	$5.29	$670,290.61
6/11/2013	Domain Partners Vi, L.P.	Major Shareholder	Sell	5,337	$5.00	$26,685.00
5/17/2013	David Holland	SVP	Sell	30,000	$4.13	$123,900.00
5/16/2013	Domain Partners Vi, L.P.	Major Shareholder	Sell	44,242	$4.60	$203,513.20
12/13/2012	Peter J Pizzo III	Director	Buy	5,000	$1.44	$7,200.00
12/3/2012	C. Daniel Myers	CEO	Sell	7,700	$1.95	$15,015.00

(Data available from 1/1/2013 forward)

Latest Headlines for Alimera Sciences (NASDAQ:ALIM)

Date	Headline
	Keen Investors Find News on Alimera Sciences, Inc. (NASDAQ:ALIM) - Duncan Research (NASDAQ:ALIM) www.duncanindependent.com - September 24 at 3:24 PM
	Under the Microscope, Zeroing in at Alimera Sciences, Inc. (NASDAQ:ALIM) - Duncan Research (NASDAQ:ALIM) www.duncanindependent.com - September 22 at 3:24 PM
	Alimera Sciences : Announces Exercise of Underwriters Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock (NASDAQ:ALIM) www.4-traders.com - September 21 at 9:55 AM
	First Week of November 18th Options Trading For Alimera Sciences (ALIM) (NASDAQ:ALIM) www.stockoptionschannel.com - September 20 at 3:24 PM
	ETF’s with exposure to Alimera Sciences, Inc. : September 20, 2016 (NASDAQ:ALIM) www.capitalcube.com - September 20 at 3:24 PM
	Under the Microscope: Getting a Closer Look at Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - Duncan Research (NASDAQ:ALIM) www.duncanindependent.com - September 20 at 9:15 AM
	Here's Why Cowen Upgraded Alimera Sciences Inc (ALIM) Shares ... - Smarter Analyst (NASDAQ:ALIM) www.smarteranalyst.com - September 18 at 8:14 AM
	Keen Investors Seek Information on Alimera Sciences, Inc. (NASDAQ:ALIM) - Duncan Research (NASDAQ:ALIM) www.duncanindependent.com - September 16 at 3:26 PM
	Pre-Open Stock Movers 09/16: (DEPO) (INTC) (GPRO) Higher; (NVAX) (DB) (ORCL) Lower (more...) (NASDAQ:ALIM) www.streetinsider.com - September 16 at 12:06 PM
	Stock Update, a Closer Look at Alimera Sciences, Inc. (NASDAQ:ALIM) - Duncan Research (NASDAQ:ALIM) www.duncanindependent.com - September 15 at 3:24 PM
	Alimera Sciences Incorporated (NASDAQ:ALIM) Short Interest Decreased By 38.05% - Frisco Fastball (NASDAQ:ALIM) friscofastball.com - September 14 at 3:24 PM
	Keen Investors Narrowing Their Focus on Alimera Sciences, Inc. (NASDAQ:ALIM) - Duncan Research (NASDAQ:ALIM) www.duncanindependent.com - September 14 at 3:24 PM
	PSIVIDA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) (NASDAQ:ALIM) www.4-traders.com - September 14 at 8:58 AM
	Penny Stock Investors Highly Curious in Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - Duncan Research (NASDAQ:ALIM) www.duncanindependent.com - September 13 at 3:25 PM
	Alimera Sciences Announces 23 Clinical Presentations and a Sponsored Symposium at 16th EURETINA Congress - GlobeNewswire (press release) (NASDAQ:ALIM) globenewswire.com - September 6 at 8:33 PM
	Alimera Sciences Announces 23 Clinical Presentations and a Sponsored Symposium at 16th EURETINA Congress (NASDAQ:ALIM) finance.yahoo.com - September 6 at 8:12 AM
	Diabetic Retinopathy Treatment World Market Segmentation and Major Players Analysis 2022 (NASDAQ:ALIM) world.einnews.com - September 2 at 8:04 AM
	Alimera: Reassessing The Thesis After The Equity Raise - Seeking Alpha (NASDAQ:ALIM) seekingalpha.com - August 25 at 3:28 PM
	BRIEF-Crown castle announces pricing of senior notes offering (NASDAQ:ALIM) uk.reuters.com - August 23 at 8:43 PM
	Alimera Sciences Inc (ALIM): Great Point Partners Reveals 5.12% Stake - Insider Monkey (blog) (NASDAQ:ALIM) www.insidermonkey.com - August 23 at 3:26 PM
	Alimera Sciences Inc (ALIM): Great Point Partners Reveals 5.12% Stake (NASDAQ:ALIM) feedproxy.google.com - August 23 at 9:41 AM
	BRIEF-Great point reports 5.12 pct passive stake in Alimera Sciences - SEC... - Reuters (NASDAQ:ALIM) www.reuters.com - August 22 at 8:35 PM
	Alimera Sciences, Inc. (NASDAQ:ALIM) Near to Lift Curtain on September 2016 Earnings - The Voice Registrar (NASDAQ:ALIM) voiceregistrar.com - August 17 at 8:55 PM
	Alimera Sciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $26.5 Million Offering of ... - GlobeNewswire (press release) (NASDAQ:ALIM) globenewswire.com - August 17 at 11:39 AM
	New Study: Alimera Sciences, Inc. (ALIM) - Financial and Strategic SWOT Analysis Review (NASDAQ:ALIM) www.live-pr.com - August 16 at 8:44 PM
	Alimera Sciences Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock (NASDAQ:ALIM) finance.yahoo.com - August 16 at 8:44 PM
	Alimera Sciences Announces Exercise of Underwriters' Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock (NASDAQ:ALIM) www.publicnow.com - August 16 at 8:44 PM
	Stocks Under Consideration: Alimera Sciences Inc (NASDAQ:ALIM), HP Inc (NYSE:HPQ) - NYSE Journal (press release) (NASDAQ:ALIM) stockznews.com - August 15 at 3:28 PM
	ALIMERA SCIENCES INC Financials (NASDAQ:ALIM) finance.yahoo.com - August 13 at 3:24 PM
	Newell Brands Inc (NYSE:NWL) & Alimera Sciences (NASDAQ:ALIM) Stocks in the News - Money News (press release) (NASDAQ:ALIM) www.newsismoney.com - August 12 at 3:34 PM
	ETF’s with exposure to Alimera Sciences, Inc. : August 12, 2016 (NASDAQ:ALIM) www.capitalcube.com - August 12 at 3:34 PM
	Alimera Sciences (ALIM) Prices 18M Common Stock Offering at $1.40/Share (NASDAQ:ALIM) www.streetinsider.com - August 12 at 12:00 PM
	Alimera Sciences Prices Public Offering of Common Stock - GlobeNewswire (press release) (NASDAQ:ALIM) globenewswire.com - August 11 at 9:17 PM
	Alimera Sciences Prices Public Offering of Common Stock - Yahoo Finance (NASDAQ:ALIM) finance.yahoo.com - August 11 at 3:28 PM
	Alimera Sciences Proposes Public Offering of Common Stock - Yahoo Finance (NASDAQ:ALIM) finance.yahoo.com - August 11 at 12:40 PM
	8:42 am Alimera Sciences prices an 18 mln share underwritten public offering of common stock at $1.40/share for gross proceeds of ~$25.2 mln (NASDAQ:ALIM) finance.yahoo.com - August 11 at 12:40 PM
	ALIMERA SCIENCES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events (NASDAQ:ALIM) biz.yahoo.com - August 11 at 12:40 PM
	Alimera Sciences Prices Public Offering of Common Stock (NASDAQ:ALIM) www.publicnow.com - August 11 at 12:40 PM
	Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016 (NASDAQ:ALIM) www.capitalcube.com - August 11 at 12:40 PM
	After-Hours Stock Movers 08/10: (KURA) (ANW) (CHK) Higher; (AVGR) (OMER) (SHAK) Lower (more...) (NASDAQ:ALIM) www.streetinsider.com - August 10 at 9:53 PM
	ALIMERA SCIENCES INC Files SEC form 8-K, Other Events (NASDAQ:ALIM) biz.yahoo.com - August 10 at 9:53 PM
	Alimera Sciences Proposes Public Offering of Common Stock (NASDAQ:ALIM) www.publicnow.com - August 10 at 9:53 PM
	Vigorous Movers' Roundup- American Airlines (NASDAQ:AAL), Alimera Sciences (NASDAQ:ALIM), Medivation ... - Seneca Globe (NASDAQ:ALIM) www.senecaglobe.com - August 10 at 3:47 PM
	Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting - Nasdaq (NASDAQ:ALIM) www.nasdaq.com - August 9 at 4:31 PM
	Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting (NASDAQ:ALIM) www.publicnow.com - August 9 at 12:11 PM
	Alimera Sciences Inc. (ALIM) Drops 12% on August 04 - Equities.com (NASDAQ:ALIM) www.equities.com - August 6 at 11:10 AM
	ALIMERA SCIENCES INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ALIM) biz.yahoo.com - August 5 at 8:49 PM
	Edited Transcript of ALIM earnings conference call or presentation 4-Aug-16 2:00pm GMT (NASDAQ:ALIM) finance.yahoo.com - August 5 at 8:49 PM
	Price Target by Analysts: VEREIT, Inc. (NYSE:VER), Alimera Sciences, Inc. (NASDAQ:ALIM) - News Oracle (NASDAQ:ALIM) www.newsoracle.com - August 5 at 3:26 PM
	Stocks inside Analysts Spotlight: Alimera Sciences, Inc. (NASDAQ:ALIM) , Merrimack Pharmaceuticals, Inc. (NASDAQ ... - Street Updates (NASDAQ:ALIM) www.streetupdates.com - August 5 at 3:26 PM